If the sheep trials revealed that the technology wasn’t working as well as expected (Like some here suggested) why didn’t the company use the opportunity of the Axovant termination announcement to abandon OPMD altogether and instead put the 22 million at work going after other indications? It would have been the best time to walk away from OPMD because the share price was reflecting this anyhow. Yet, they didn’t.
There is only one possible explanation - The OPMD program is progressing very well and Benitec just wants to tweak the delivery method, nothing more.
Axovant has not publicly or privately (through leaks) said OPMD didn’t work. And they hardly started work on the other proposed indications so the reason to abandon the agreement seems related to their own company limitations - they simply took on too many programs.
I expect good news on OPMD very soon. Add this to a program that is fully funded and 100% ours and we could see a massive, funicular rise in share price.
Add to My Watchlist
What is My Watchlist?